Page last updated: 2024-10-30

losartan and Aging

losartan has been researched along with Aging in 75 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
" We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension."8.12Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022)
"The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II."7.71Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001)
"The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors."7.70Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)
" In conclusion, (1) diminished EDHF availability accounts for the reduced Ach-relaxations produced by aging in MVB from SHR; (2) the enhancement of Ach-relaxations produced by losartan seems to be dependent on an increased NO availability; and (3) angiotensin II via angiotensin I type 1 receptor (AT1) plays an important role in the deleterious consequences of aging on endothelial function in SHR."7.70Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)
" In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure."7.70Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998)
" At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason."6.40The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998)
"Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0."5.40Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014)
"Treatment with Losartan resulted in severe renal abnormalities."5.35Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008)
" We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension."4.12Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022)
", the aging model group, the high dose CH group, the middle dose CH group, the low dose CH group, the Losartan group, 17 in each group."3.81[Intervention Mechanism of Extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on Adventitia of Senescent Rats]. ( Lei, Y; Liu, JG; Wang, Y; Yang, J, 2015)
" Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs)."3.75Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. ( Grujić-Milanović, J; Ivanov, M; Jovović, D; Mihailović-Stanojević, N; Miloradović, Z, 2009)
" This study was designed to determine the effects of aging and AT-1 receptor blockade (losartan 30 mg/kg/day beginning at 8 weeks of age) on NO system in this model."3.71Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. ( Kivlighn, S; Ni, ZN; Shahinfar, S; Vaziri, ND; Wang, XQ, 2002)
"The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II."3.71Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001)
" Accordingly, ingestion of chromium and antioxidants which improve insulin sensitivity and/or lessen free radical formation could theoretically ameliorate these basic disorders and lessen signs and symptoms of chronic age-related disorders."3.71Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. ( Bagchi, D; Echard, B; Montamarry, S; Preuss, HG; Scheckenbach, R, 2001)
"The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors."3.70Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)
" In conclusion, (1) diminished EDHF availability accounts for the reduced Ach-relaxations produced by aging in MVB from SHR; (2) the enhancement of Ach-relaxations produced by losartan seems to be dependent on an increased NO availability; and (3) angiotensin II via angiotensin I type 1 receptor (AT1) plays an important role in the deleterious consequences of aging on endothelial function in SHR."3.70Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)
" In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure."3.70Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998)
" This report emphasizes the importance of angiotensin II in vascular function alterations induced by aging in SHR."3.70Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1999)
"In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect."2.42Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. ( Gard, PR, 2004)
"Losartan was the first drug in this class to become commercially available."2.40Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997)
" At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason."2.40The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998)
"Treatment with losartan (0."1.46miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. ( Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J, 2017)
"Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0."1.40Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014)
"Treatment with losartan (15 mg/kg/day; n = 9) similarly mitigated signs of cardiac oxidative stress, but impairments in diastolic function persisted when compared with untreated rats (n = 7)."1.38Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats. ( Carter, CS; Groban, L; Kassik, KA; Lin, MS; Lindsey, S; Machado, FS; Wang, H, 2012)
"Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart."1.36Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010)
"Treatment with Losartan resulted in severe renal abnormalities."1.35Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008)
"Late losartan treatment had no effect on any of the parameters in either kidney, and PD-123319 had no effect on either kidney."1.34Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. ( Burt, LE; Chevalier, RL; Coleman, CM; Forbes, MS; Minor, JJ; Thornhill, BA, 2007)
"Although cardiac hypertrophy in hypertension has been well recognized, the molecular mechanisms for the development of hypertrophy are still largely unknown."1.33Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. ( Chen, GQ; Chen, WL; Fang, NY; Jin, X; Liu, ZG; Shi, JZ; Wang, LS; Xia, L; Zhang, L; Zheng, Y, 2006)
"Captopril treatment partially reversed low insulin sensitivity in LSD rats, whereas losartan did not change it, which indicates that the effect of LSD on insulin sensitivity is angiotensin independent."1.31High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats. ( Dolnikoff, MS; Furukawa, LN; Heimann, JC; Machado, UF; Okamoto, MM; Prada, P, 2000)
"Body weights were 10% lower in the LO group at the start but remained unchanged relative to the CO group during the entire 8-day period of observation."1.31AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring. ( Butler, DG; Midgely, A; Nemati, B; Pak, SH, 2002)

Research

Studies (75)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's24 (32.00)18.2507
2000's33 (44.00)29.6817
2010's14 (18.67)24.3611
2020's4 (5.33)2.80

Authors

AuthorsStudies
van Thiel, BS1
van der Linden, J1
Ridwan, Y1
Garrelds, IM1
Vermeij, M1
Clahsen-van Groningen, MC1
Qadri, F1
Alenina, N1
Bader, M1
Roks, AJM1
Danser, AHJ1
Essers, J1
van der Pluijm, I1
Shimizu, S1
Nagao, Y1
Kurabayashi, A1
Shimizu, T1
Higashi, Y1
Karashima, T1
Saito, M1
Qureshi, AW1
Altamimy, R1
El Habhab, A1
El Itawi, H1
Farooq, MA1
Zobairi, F1
Hasan, H1
Amoura, L1
Kassem, M1
Auger, C1
Schini-Kerth, V1
Toti, F1
Wang, Y4
Cong, R1
Tian, Y1
Chen, C1
Zhang, Q1
Zhou, X1
Ji, C1
Meng, X1
Song, N1
Hori, D1
Dunkerly-Eyring, B1
Nomura, Y1
Biswas, D1
Steppan, J1
Henao-Mejia, J1
Adachi, H1
Santhanam, L1
Berkowitz, DE1
Steenbergen, C1
Flavell, RA1
Das, S1
Hamatani, H1
Eng, DG1
Kaverina, NV1
Gross, KW1
Freedman, BS1
Pippin, JW1
Shankland, SJ1
Tao, H1
Rui, C1
Zheng, J1
Tang, J1
Wu, L1
Shi, A1
Chen, N1
He, R1
Wu, C1
Li, J1
Yin, X1
Zhang, P1
Zhu, Z1
Tao, J1
Xiao, J1
Mao, C1
Xu, Z1
Lin, CH1
Yang, H1
Xue, QL1
Chuang, YF1
Roy, CN1
Abadir, P1
Walston, JD2
Lei, Y1
Yang, J1
Liu, JG1
Costa, G1
Garabito, M1
Jiménez-Altayó, F1
Onetti, Y1
Sabate, M1
Vila, E1
Dantas, AP1
Ognibene, DT1
Oliveira, PR1
Marins de Carvalho, LC1
Costa, CA1
Espinoza, LA1
Criddle, DN1
Tano, T1
Soares de Moura, R1
Resende, AC1
Senador, D1
Kanakamedala, K1
Irigoyen, MC1
Morris, M1
Elased, KM1
Chan, EC1
Jones, GT1
Dusting, GJ1
Datla, SR1
Jiang, F1
Inserra, F3
Basso, N4
Ferder, M1
Userpater, M1
Stella, I2
Paglia, N1
Inserra, P1
Tenembaum, D1
Ferder, L3
Mihailović-Stanojević, N1
Miloradović, Z1
Grujić-Milanović, J1
Ivanov, M1
Jovović, D1
Sumbalová, Z1
Kucharská, J1
Kristek, F1
Stein, M1
Boulaksil, M1
Jansen, JA1
Herold, E1
Noorman, M1
Joles, JA1
van Veen, TA1
Houtman, MJ1
Engelen, MA1
Hauer, RN1
de Bakker, JM1
van Rijen, HV1
Hobara, N2
Goda, M2
Hashikawa, N1
Jin, X2
Zamami, Y1
Takatori, S1
Kawasaki, H2
Carter, CS3
Giovannini, S1
Giovaninni, S1
Seo, DO1
DuPree, J1
Morgan, D1
Chung, HY2
Lees, H1
Daniels, M1
Hubbard, GB1
Lee, S1
Ikeno, Y1
Foster, TC1
Buford, TW1
Marzetti, E1
Kim, JM1
Heo, HS1
Choi, YJ1
Ye, BH1
Mi Ha, Y1
Seo, AY1
Yu, BP1
Leeuwenburgh, C1
Groban, L1
Lindsey, S1
Wang, H1
Lin, MS1
Kassik, KA1
Machado, FS1
Abadir, PM1
Foster, DB1
Crow, M1
Cooke, CA1
Rucker, JJ1
Jain, A1
Smith, BJ1
Burks, TN1
Cohn, RD1
Fedarko, NS1
Carey, RM2
O'Rourke, B1
Sanchis-Gomar, F1
Gómez-Cabrera, MC1
Viña, J1
Zhou, XJ1
Vaziri, ND2
Zhang, J2
Wang, HW1
Wang, XQ2
Ni, ZN1
Kivlighn, S1
Shahinfar, S1
Tedesco, MA1
Ratti, G1
Di Salvo, G1
Natale, F1
de Cavanagh, EM1
Piotrkowski, B1
Fraga, CG1
Gard, PR1
Stegbauer, J1
Vonend, O1
Oberhauser, V1
Sellin, L1
Rump, LC1
Gessei-Tsutsumi, N1
Takayama, F1
Akiyama, S1
Kurosaki, Y1
Wang, M1
Spinetti, G1
Jiang, LQ1
Monticone, R1
Zhao, D1
Cheng, L1
Krawczyk, M1
Talan, M1
Pintus, G1
Lakatta, EG1
Demirci, B1
McKeown, PP1
Bayraktutan, U1
Tuttle, JB1
Hannan, JL1
Smallegange, C1
Hale, TM1
Heaton, JP1
Adams, MA1
Xia, L1
Wang, LS1
Shi, JZ1
Zheng, Y1
Chen, WL1
Zhang, L1
Liu, ZG1
Chen, GQ1
Fang, NY1
Yanes, LL1
Romero, DG1
Iles, JW1
Iliescu, R1
Gomez-Sanchez, C1
Reckelhoff, JF1
McGrath, JC1
Baumann, M2
Janssen, BJ1
Hermans, JJ1
Peutz-Kootstra, C1
Witzke, O1
Smits, JF2
Struijker Boudier, HA1
Coleman, CM1
Minor, JJ1
Burt, LE1
Thornhill, BA1
Forbes, MS1
Chevalier, RL2
Palmieri, V1
Pini, R1
Chiara Cavallini, M1
Cini, R1
Pietrelli, A1
Terragno, NA2
Bartholome, R1
Peutz-Kootstra, CJ1
Struijker-Boudier, HA1
Lee, JH1
Xia, S1
Ragolia, L1
Sánchez, SI1
Seltzer, AM1
Fuentes, LB1
Forneris, ML1
Ciuffo, GM1
Nishimura, N1
Takase, H1
Morita, T1
Fornes, P1
Richer, C1
Vacher, E1
Bruneval, P1
Giudicelli, JF1
Cai, G1
Gurdal, H1
Seasholtz, TM1
Johnson, MD1
Ruzicka, M1
Keeley, FW1
Leenen, FH1
Tufro-McReddie, A2
Johns, DW1
Geary, KM1
Dagli, H1
Everett, AD1
Gomez, RA2
Tank, JE1
Vora, JP1
Houghton, DC1
Anderson, S1
Díaz-Torga, GS1
Becú-Villalobos, D1
Libertun, C1
Baylis, C1
Pitt, B2
Chang, P1
Timmermans, PB1
Breault, L1
Lehoux, JG1
Gallo-Payet, N1
Burrell, LM1
Johnston, CI1
Sil, P1
Sen, S1
Carvalho, CR1
Thirone, AC1
Gontijo, JA1
Velloso, LA1
Saad, MJ1
Nakano, N1
Moriguchi, A1
Morishita, R1
Kida, I1
Tomita, N1
Matsumoto, K1
Nakamura, T1
Higaki, J1
Ogihara, T1
Aronow, WS1
Maeso, R3
Rodrigo, E3
Muñoz-García, R2
Navarro-Cid, J3
Ruilope, LM3
Cachofeiro, V3
Lahera, V3
Conlin, PR1
Elkins, M1
Liss, C1
Vrecenak, AJ1
Barr, E1
Edelman, JM1
Yoneda, H1
Toriumi, W1
Ohmachi, Y1
Okumura, F1
Fujimura, H1
Nishiyama, S1
Touyz, RM1
Endemann, D1
He, G1
Li, JS1
Schiffrin, EL1
Nowicki, PT1
Minnich, LA1
Prada, P1
Okamoto, MM1
Furukawa, LN1
Machado, UF1
Heimann, JC1
Dolnikoff, MS1
Ma, LJ1
Nakamura, S1
Whitsitt, JS1
Marcantoni, C1
Davidson, JM1
Fogo, AB1
González Bosc, LV1
Kurnjek, ML1
Müller, A1
Preuss, HG1
Montamarry, S1
Echard, B1
Scheckenbach, R1
Bagchi, D1
Butler, DG1
Pak, SH1
Midgely, A1
Nemati, B1
Rajagopalan, S1
Brook, R1
Mehta, RH1
Supiano, M1
Kubo, T1
Ibusuki, T1
Chiba, S1
Kambe, T1
Fukumori, R1
Arrizurieta, EE1
Brocca, S1
Tsutsumi, K1
Saavedra, JM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Study of Muscle Strength Maintenance in Older Adults[NCT01989793]Phase 237 participants (Actual)Interventional2013-07-31Completed
Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure[NCT03371823]Phase 48 participants (Actual)Interventional2017-09-01Terminated (stopped due to We experienced challenges recruiting unmedicated women with high blood pressure for the intervention.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 16 (i.e., baseline minus week 16) was the outcome of the analysis. A negative number indicates decrease in strength from week 0 to week 16." (NCT01989793)
Timeframe: Baseline to Week 16

InterventionNewton (Mean)
Losartan-7.40
Placebo-4.27

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 24 (i.e., baseline minus week 24) was the outcome of the analysis. A negative number indicates a decrease in strength from week 0 to week 24." (NCT01989793)
Timeframe: Baseline to Week 24

InterventionNewton (Mean)
Losartan-9.20
Placebo-7.00

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 8 (i.e., baseline minus week 8) was the outcome of the analysis. A negative number indicates that there was a decrease in isokinetic strength from week 0 to week 8." (NCT01989793)
Timeframe: Baseline to Week 8

InterventionNewton (Mean)
Losartan-4.90
Placebo-4.73

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 16

Interventionpercentage of work (Mean)
Losartan16.51
Placebo8.77

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 24

Interventionpercentage of work (Mean)
Losartan17.07
Placebo9.05

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to the total work in the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 8

Interventionpercentage of work (Mean)
Losartan14.29
Placebo7.87

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 16 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 16 weeks

InterventionParticipants (Count of Participants)
Losartan3
Placebo5

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 24 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 24 weeks

InterventionParticipants (Count of Participants)
Losartan3
Placebo5

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 8 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 8 weeks

InterventionParticipants (Count of Participants)
Losartan3
Placebo6

ET-1 Mediated Constriction

Cutaneous blood flow is measured via laser Doppler flowmetry during cutaneous microdialysis perfusions of ET-A and ET-B receptor antagonists as previously described by Wenner MM in 2017(see reference list). (NCT03371823)
Timeframe: Each participant was assessed at baseline and 2 weeks later.

Intervention% change blood flow flux (Mean)
ETA blockadeETB blockade
Normotensive43742

Reviews

6 reviews available for losartan and Aging

ArticleYear
[Role of angiontensin receptors in remodeling perivascular nerves].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:11

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; C

2010
Does the angiotensin II receptor antagonist losartan improve cognitive function?
    Drugs & aging, 2002, Volume: 19, Issue:10

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver

2002
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
    Expert opinion on therapeutic targets, 2004, Volume: 8, Issue:1

    Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2004
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
    Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:5

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi

1995
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
    Drugs & aging, 1997, Volume: 10, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi

1997
The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.
    Drugs & aging, 1998, Volume: 12, Issue:6

    Topics: Aged; Aging; Angiotensin Receptor Antagonists; Antihypertensive Agents; Evaluation Studies as Topic;

1998

Trials

3 trials available for losartan and Aging

ArticleYear
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
    Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:5

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi

1995
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.
    Journal of human hypertension, 1998, Volume: 12, Issue:10

    Topics: Aged; Aging; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug

1998
Effect of losartan in aging-related endothelial impairment.
    The American journal of cardiology, 2002, Mar-01, Volume: 89, Issue:5

    Topics: Aged; Aged, 80 and over; Aging; Blood Pressure; Brachial Artery; Cell Adhesion Molecules; Chemokine

2002

Other Studies

67 other studies available for losartan and Aging

ArticleYear
In Vivo Renin Activity Imaging in the Kidney of Progeroid
    International journal of molecular sciences, 2021, Nov-18, Volume: 22, Issue:22

    Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA

2021
Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
    European journal of pharmacology, 2022, May-05, Volume: 922

    Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr

2022
Ageing enhances the shedding of splenocyte microvesicles with endothelial pro-senescent effect that is prevented by a short-term intake of omega-3 PUFA EPA:DHA 6:1.
    Biochemical pharmacology, 2020, Volume: 173

    Topics: Aging; Animals; Antihypertensive Agents; Biomarkers; Cell-Derived Microparticles; Cells, Cultured; C

2020
Restoration of erectile function by suppression of corporal apoptosis and oxidative stress with losartan in aged rats with erectile dysfunction.
    Andrology, 2020, Volume: 8, Issue:3

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Erectile Dysfunction; Losartan; Male; Oxida

2020
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiovascular Disea

2017
Lineage tracing aged mouse kidneys shows lower number of cells of renin lineage and reduced responsiveness to RAAS inhibition.
    American journal of physiology. Renal physiology, 2018, 07-01, Volume: 315, Issue:1

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor

2018
Angiotensin II-mediated vascular changes in aged offspring rats exposed to perinatal nicotine.
    Peptides, 2013, Volume: 44

    Topics: Acetylcholine; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdom

2013
Losartan improves measures of activity, inflammation, and oxidative stress in older mice.
    Experimental gerontology, 2014, Volume: 58

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Catalase; Disease

2014
[Intervention Mechanism of Extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on Adventitia of Senescent Rats].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2015, Volume: 35, Issue:12

    Topics: Adventitia; Aging; Angiotensin II; Animals; Aorta, Thoracic; Drugs, Chinese Herbal; Losartan; Panax;

2015
Sex differences in angiotensin II responses contribute to a differential regulation of cox-mediated vascular dysfunction during aging.
    Experimental gerontology, 2016, 12-01, Volume: 85

    Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 2; Endotheli

2016
Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors.
    Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:1

    Topics: Acetylcholine; Aging; Angiotensin II; Animals; Blotting, Western; Bradykinin; Gene Expression Regula

2009
Cardiovascular and autonomic phenotype of db/db diabetic mice.
    Experimental physiology, 2009, Volume: 94, Issue:6

    Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B

2009
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
    Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:9

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas

2009
Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
    Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5

    Topics: Actins; Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I

2009
Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats.
    General physiology and biophysics, 2009, Volume: 28 Spec No

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly;

2009
Losartan improved respiratory function and coenzyme Q content in brain mitochondria of young spontaneously hypertensive rats.
    Cellular and molecular neurobiology, 2010, Volume: 30, Issue:5

    Topics: Aging; alpha-Tocopherol; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Brain; Cell

2010
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
    American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr

2010
Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 × Brown Norway rats.
    Age (Dordrecht, Netherlands), 2011, Volume: 33, Issue:2

    Topics: Adiposity; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal

2011
Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney.
    Experimental gerontology, 2011, Volume: 46, Issue:7

    Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi

2011
Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.
    Age (Dordrecht, Netherlands), 2012, Volume: 34, Issue:4

    Topics: Aging; Analysis of Variance; Animals; Arterial Pressure; Diastole; Disease Models, Animal; Dose-Resp

2012
Identification and characterization of a functional mitochondrial angiotensin system.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Sep-06, Volume: 108, Issue:36

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Autocrine Communication; Cell Line; Chronic

2011
The loss of muscle mass and sarcopenia: non hormonal intervention.
    Experimental gerontology, 2011, Volume: 46, Issue:12

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates

2011
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
    Kidney international, 2002, Volume: 62, Issue:3

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension,

2002
Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR.
    Biochimica et biophysica acta, 2002, Oct-21, Volume: 1592, Issue:2

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pr

2002
Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:9

    Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Res

2003
Angiotensin II receptor modulation of renal vascular resistance and neurotransmission in young and adult spontaneously hypertensive rats.
    Kidney & blood pressure research, 2005, Volume: 28, Issue:1

    Topics: Aging; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Imidazoles; Kidney; Losartan

2005
Long-term inhibition of angiotensin prevents reduction of periarterial innervation of calcitonin gene-related peptide (CGRP)-containing nerves in spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:5

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; C

2005
Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.
    The American journal of pathology, 2005, Volume: 167, Issue:5

    Topics: Adrenergic alpha-Agonists; Aging; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure;

2005
Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.
    Journal of hypertension, 2005, Volume: 23, Issue:12

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; B

2005
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
    Journal of hypertension, 2006, Volume: 24, Issue:1

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys

2006
Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
    Journal of hypertension, 2006, Volume: 24, Issue:1

    Topics: Aging; Animals; Antihypertensive Agents; Apomorphine; Blood Pressure; Enalapril; Hydralazine; Hydroc

2006
Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats.
    Proteomics, 2006, Volume: 6, Issue:6

    Topics: Age Factors; Aging; Algorithms; Animals; Antihypertensive Agents; Blotting, Western; Cardiomegaly; D

2006
Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2006, Volume: 291, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aging; Angiotensins; Animals; Antihypertensive Agents; Female; Kidney;

2006
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
    Journal of hypertension, 2007, Volume: 25, Issue:1

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood

2007
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
    Journal of hypertension, 2007, Volume: 25, Issue:1

    Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C

2007
Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
    American journal of physiology. Renal physiology, 2007, Volume: 293, Issue:1

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin

2007
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach

2007
Protective effect of long-term angiotensin II inhibition.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:3

    Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi

2007
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?
    American journal of hypertension, 2008, Volume: 21, Issue:2

    Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Cycle; Cell Division; Hyperplasia; Hyp

2008
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 295, Issue:1

    Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Endothelium, Vas

2008
Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney.
    European journal of pharmacology, 2008, Jun-24, Volume: 588, Issue:1

    Topics: Abnormalities, Drug-Induced; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiote

2008
[Effects of chronic losartan treatment on myocardial, vascular structure and reactivity with aging in spontaneously hypertensive rats (SHR): its effects compared with those of captopril].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1995, Volume: 105, Issue:6

    Topics: Aging; Animals; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Captopril; Coronary C

1995
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal.
    Journal of cardiovascular pharmacology, 1993, Volume: 22, Issue:2

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood

1993
Age-related changes in angiotensin II-stimulated vascular contraction and inositol phosphate accumulation in Fischer 344 rats.
    Mechanisms of ageing and development, 1994, Oct-20, Volume: 76, Issue:2-3

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Arteries; Bipheny

1994
The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.
    Circulation, 1994, Volume: 90, Issue:4

    Topics: Aging; Animals; Biphenyl Compounds; Blood Pressure; Collagen; Coronary Circulation; Elastin; Enalapr

1994
Angiotensin II type 1 receptor: role in renal growth and gene expression during normal development.
    The American journal of physiology, 1994, Volume: 266, Issue:6 Pt 2

    Topics: Aging; Animals; Animals, Newborn; Biphenyl Compounds; Blood Pressure; Gene Expression; Imidazoles; K

1994
Altered renal vascular responses in the aging rat kidney.
    The American journal of physiology, 1994, Volume: 266, Issue:6 Pt 2

    Topics: Aging; Angiotensin II; Animals; Arginine; Biphenyl Compounds; Blood Pressure; Endothelins; Glomerula

1994
Ontogeny of angiotensin-II-induced prolactin release in vivo and in vitro in female and male rats.
    Neuroendocrinology, 1994, Volume: 59, Issue:1

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response

1994
Renal responses to acute angiotensin II inhibition and administered angiotensin II in the aging, conscious, chronically catheterized rat.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1993, Volume: 22, Issue:6

    Topics: Age Factors; Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Comp

1993
Angiotensin II receptors in the human adrenal gland.
    Endocrine research, 1996, Volume: 22, Issue:4

    Topics: Adrenal Glands; Adult; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Autoradiography; Bin

1996
Angiotensin II and myocyte growth: role of fibroblasts.
    Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:2 Pt 1

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compoun

1997
Effect of captopril, losartan, and bradykinin on early steps of insulin action.
    Diabetes, 1997, Volume: 46, Issue:12

    Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Captopril; Ins

1997
Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:6

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A

1997
Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats.
    Journal of hypertension, 1998, Volume: 16, Issue:5

    Topics: Aging; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Hypertension; Losartan; Male; Rats;

1998
Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR.
    Kidney international. Supplement, 1998, Volume: 68

    Topics: Acetylcholine; Aging; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Dose-Respons

1998
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
    European journal of pharmacology, 1998, Dec-04, Volume: 362, Issue:2-3

    Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B

1998
Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:1 Pt 2

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Imid

1999
Effects of systemic hypotension on postnatal intestinal circulation: role of angiotensin.
    The American journal of physiology, 1999, Volume: 276, Issue:2

    Topics: Aging; Angiotensin II; Animals; Animals, Newborn; Hemodynamics; Hypotension; In Vitro Techniques; In

1999
Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats.
    American journal of hypertension, 1999, Volume: 12, Issue:11 Pt 1

    Topics: Acetylcholine; Adrenergic alpha-Antagonists; Aging; Angiotensin II; Animals; Antihypertensive Agents

1999
High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:1 Pt 2

    Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biological Transp

2000
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
    Kidney international, 2000, Volume: 58, Issue:6

    Topics: Aging; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Aorta, Thor

2000
Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging.
    Journal of hypertension, 2001, Volume: 19, Issue:8

    Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; A

2001
Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats.
    Molecular and cellular biochemistry, 2001, Volume: 223, Issue:1-2

    Topics: Aging; Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Body Weight; Chrom

2001
AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring.
    Regulatory peptides, 2002, Apr-15, Volume: 105, Issue:1

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Appetite; Blood Pressure; Body Weight; Carotid Art

2002
Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats.
    Clinical and experimental pharmacology & physiology, 2002, Volume: 29, Issue:7

    Topics: Aging; Animals; Aorta, Thoracic; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activatio

2002
Dietary protein modulates intrarenal distribution of renin and its mRNA during development.
    The American journal of physiology, 1992, Volume: 263, Issue:3 Pt 2

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Body Weight;

1992
Differential development of angiotensin II receptor subtypes in the rat brain.
    Endocrinology, 1991, Volume: 128, Issue:1

    Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Brain; Im

1991